

# Bayesian Prediction of Severe Outcomes in the **LabMarCS: Laboratory Markers of COVID-19 Severity - Bristol Cohort**

Brian Sullivan<sup>a,\*</sup>, Edward Barker<sup>a</sup>, Philip Williams<sup>c</sup>, Louis MacGregor<sup>a</sup>, Ranjeet Bhamber<sup>a</sup>, Matt Thomas<sup>b</sup>, Stefan Gurney<sup>c</sup>, Catherine Hyams<sup>a,b</sup>, Alastair Whiteway<sup>b</sup>, Jennifer A Cooper<sup>a</sup>, Chris McWilliams<sup>a</sup>, Katy Turner<sup>a</sup>, Andrew W. Dowsey<sup>a</sup>, Mahableshwar Albur<sup>b</sup>

<sup>a</sup>University Of Bristol

<sup>b</sup>Southmead Hospital, North Bristol NHS Trust

<sup>c</sup>University Hospitals Bristol and Weston NHS Trust

## Abstract

**Objectives:** To develop cross-validated prediction models for severe outcomes in COVID-19 using blood biomarker and demographic data; Demonstrate best practices for clinical data curation and statistical modelling decisions, with an emphasis on Bayesian methods.

**Design:** Retrospective observational cohort study.

**Setting:** Multicentre across National Health Service (NHS) trusts in Southwest region, England, UK.

**Participants:** Hospitalised adult patients with a positive SARS-CoV 2 by PCR during the first wave (March – October 2020). 843 COVID-19 patients (mean age 71, 45% female, 32% died or needed ICU stay) split into training (n=590) and validation groups (n=253) along with observations on demographics, co-infections, and 30 laboratory blood biomarkers.

**Primary outcome measures:** ICU admission or death within 28-days of admission to hospital for COVID-19 or a positive PCR result if already admitted.

**Results:** Predictive regression models were fit to predict primary outcomes using demographic data and initial results from biomarker tests collected within 3 days of admission or testing positive if already admitted. Using all variables, a standard logistic regression yielded an internal validation median AUC of 0.7 (95% Interval [0.64,0.81]), and an external validation AUC of 0.67 [0.61, 0.71], a Bayesian logistic regression using a horseshoe prior yielded an internal validation median AUC of 0.78 [0.71, 0.85], and an external validation median AUC of 0.70 [0.68, 0.71]. Variable selection performed using Bayesian predictive projection determined a four variable model using Age, Urea, Prothrombin time and Neutrophil-Lymphocyte ratio, with a median AUC of 0.74 [0.67, 0.82], and external validation AUC of 0.70 [0.69, 0.71].

**Conclusions:** Our study reiterates the predictive value of previously identified biomarkers for COVID-19 severity assessment. Given the small data set, the full and reduced models have decent performance, but would require improved external validation for clinical application. The study highlights a variety of challenges present in complex medical data sets while maintaining best statistical practices with an emphasis on showcasing recent Bayesian methods.

## 1 Introduction

2 Globally, as of 14 July 2022, there have been 556 million  
3 confirmed cases of COVID-19, including 6.35 million deaths,  
4 with 23.1 million cases in the UK, resulting in over 181,000  
5 deaths (WHO Coronavirus (COVID-19) Dashboard, <https://covid19.who.int/>). COVID-19 has a wide spectrum of  
6 clinical features ranging from asymptomatic to severe systemic  
7 illness with a significant attributable mortality, while clinical  
8 manifestations are variable especially in the most vulnerable  
9 groups and immunocompromised people [1]. COVID-19 is a  
10 multi-system disease resulting in the derangements of home-  
11 ostasis affecting pulmonary, cardiovascular, coagulation, haema-  
12 tological, oxygenation, hepatic, renal and fluid balance [2, 3, 4,

14 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. Although the major-  
15 ity of people with COVID-19 will have mild or no symptoms,  
16 a small but significant proportion will suffer from a severe in-  
17 fection needing hospitalisation for supportive care, oxygen, or  
18 admission to intensive care units(ICU) for respiratory support.

19 Early identification of hospitalised COVID-19 patients who  
20 are likely to deteriorate, i.e. transfer to ICU or who may die,  
21 is vital for clinical decision making. Healthcare systems across  
22 the world including highly developed countries continue to face  
23 challenges in terms of capacity and resources to manage this  
24 pandemic, as lock down measures have been relaxed, including  
25 opening of schools and businesses.

26 Published prediction models to date have evaluated case  
27 level factors that might predict poor outcomes (critical illness  
28 or death). A recent living systematic review [17] identified 265  
29 prognostic models for mortality and 84 for progression to se-  
30 vere or critical state. The majority of the studies looked at vital  
31 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

\*Corresponding Authors

Email addresses: [brian.sullivan@bristol.ac.uk](mailto:brian.sullivan@bristol.ac.uk) (Brian Sullivan),  
[mahableshwar.albur@nhs.uk](mailto:mahableshwar.albur@nhs.uk) (Mahableshwar Albur)

signs, age, comorbidities, and radiological features. Models were unlikely to include a broad range of variables concerning co-infection, biochemical factors (outside of C-reactive protein), and other haematological factors on an individual patient level. Most of the prognostic models did not describe the target population or care setting adequately, did not fully describe the regression equation, showed high or unclear risk of bias and/or were inadequately evaluated for performance.

### Goals

The present study analyzes a range of laboratory blood marker values across metabolic pathways affected by COVID-19 infection (i.e. a core set of biomarkers feasible for clinical collection) and evaluates predictive models of severe outcomes. The main objectives of the study are: (1) Examine statistical associations of routinely measured physiological and blood biomarkers, and age and gender, to predict severe COVID-19 outcomes. (2) Develop cross-validated logistic regression prediction models using the best candidate biomarkers, and highlight biomarkers worthy of future research. (3) Use variable selection techniques including least absolute shrinkage and selection operator (LASSO) regularisation [18] and Bayesian Projective Prediction [19] to illustrate the process of creating a reduced model that maintains reasonable performance and is more feasible to use clinically (4) In each of these steps demonstrate best analytic practices for explaining clinical data curation and statistical modelling decisions, with an emphasis on showcasing the capabilities of recent Bayesian methods.

## Methods

### Study Cohort and Demographics

Pseudonymised data was obtained from laboratory information management system (LIMS) linking patient data for laboratory markers to key clinical outcomes. Three hospitals in the Southwest region of England, UK, participated in the study, two of them were tertiary teaching hospitals and the third was a district general hospital (DGH). A system wide data search was conducted on LIMS for all patients who tested positive for SARS-CoV-2 by polymerase chain reaction (PCR) at these three hospitals during the first wave of COVID-19 pandemic (01/03/2020 to 31/10/2020). The serial pathology data collected as a part of standard of care of patients admitted with/for COVID-19 were included- bacteriology, virology, mycology, haematology, and biochemistry. All patients testing negative for SARS CoV 2 by PCR were excluded. All laboratory markers including clinical outcomes from LIMS were extracted and the final dataset was anonymized with no patient identifying data to link back.

### Inclusion and exclusion criteria

We included all adult patients admitted to study hospitals and tested positive for SARSCoV-2 by PCR. Pediatric patients (<18 years old) and staff/healthcare workers and their household contacts were excluded. Figure 1 depicts the decision flow for inclusion and exclusion of patient data.




Figure 1: Flowchart of patient exclusion and inclusion criteria. The initial set of 1159 candidate patients was narrowed to a training set (n=590) and a validation set (n=253).

### 83 *Data Covariates*

84 The LabMarCS dataset includes a variety of host, clinical<sup>132</sup>  
85 severity indices, microbiological, immunological, haematolog-<sup>133</sup>  
86 ical and biochemistry parameters used as predictive variables<sup>134</sup>  
87 in the regression models. A full list of recorded data items is<sup>135</sup>  
88 shown in Figure 2

### 89 *Outcomes*

90 For all sites, the primary prediction outcome was death or<sup>139</sup>  
91 transfer to the ICU within 28 days of admission to hospital,<sup>140</sup>  
92 or the first positive COVID-19 PCR test result if already admit-<sup>141</sup>  
93 ted. This generally corresponds to WHO-COVID-19 Outcomes<sup>142</sup>  
94 Scale Score 6–10 (severe) versus 0–5 (mild/moderate) [20].<sup>143</sup>

### 95 *Patient Timelines*

96 The collected laboratory biomarkers are continuous mea-<sup>145</sup>  
97 sures and provide a time series representation of the course of a<sup>146</sup>  
98 patient’s admission. Figure 3 shows an example of a single pa-<sup>147</sup>  
99 tient’s readings over the course of 18 days between testing posi-<sup>148</sup>  
100 tive for COVID-19 and being released from hospital care. This<sup>149</sup>  
101 provides a representative example of the heterogeneity seen in<sup>150</sup>  
102 our dataset, i.e. not all tests are taken and others are taken regu-<sup>151</sup>  
103 larly or intermittently (further examples in Supplementary Fig-<sup>152</sup>  
104 ures S2 - S6).<sup>153</sup>

### 105 *Transformation of Biomarker Data*

106 Prediction modelling of irregularly sampled time-series data<sup>157</sup>  
107 is a challenging open research question [21]. In this study we<sup>158</sup>  
108 focused on established and available tools for conventional and<sup>159</sup>  
109 Bayesian prediction. To balance inclusion of test data not avail-<sup>160</sup>  
110 able on the day of admission and the need for clinical deci-<sup>161</sup>  
111 sions to be guided soon after admission, we chose to consider<sup>162</sup>  
112 the first value recorded for each biomarkers within three days<sup>163</sup>  
113 of their ‘critical date’. In addition, we transformed continuous<sup>164</sup>  
114 biomarkers into categorical variables via reference ranges for<sup>165</sup>  
115 clinical use in the typical healthy population ranges, see Fig-<sup>166</sup>  
116 ure 2. As an example, Figure 4 shows the histogram of read-<sup>167</sup>  
117 ings for all values recorded for Neutrophils, including clinical<sup>168</sup>  
118 thresholds to transform into categorical data. No missing data<sup>169</sup>  
119 imputation was performed, instead missingness was coded as<sup>170</sup>  
120 as an additional category ‘Test not taken’.

121 For further elaboration on the challenges of these modelling<sup>171</sup>  
122 choices, please see Discussion Section c.

### 123 **Statistical Analysis**

124 Analytics were carried out using the R statistical language<sup>176</sup>  
125 (v4.13) and R Studio (Prairie Trillium release). We used the<sup>177</sup>  
126 following packages: Standard logistic regression analyses used<sup>178</sup>  
127 the R Stats GLM package (v3.6.2); LASSO analyses, GLMnet<sup>179</sup>  
128 (v4.1-4); and for Bayesian analyses, BRMS (v2.17) and Pro-<sup>180</sup>  
129 jPred (v2.1.2). Source code for this analysis pipeline can be<sup>181</sup>  
130 found at <https://github.com/biospi/LABMARCS>.

### 131 *Analysis of Individual Biomarkers*

Before running full regression models we examined the in-  
dependent contribution of individual biomarkers in predicting  
ICU entry or death via standard logistic regressions and Bayesian  
logistic regressions with either a flat (aka uniform) or horseshoe  
prior. This allowed calculation of p-values and odds ratios for  
each biomarker. A 5-fold cross-validation repeated 20 times  
was run for each biomarker to estimate the median AUC and  
95% interquartile intervals. Each individual biomarker model  
includes age and gender (except univariate age and gender mod-  
els) and was compared against a standard model including only  
age and gender. Regressions were fit using all associated dummy  
variables for a given biomarker (e.g. ‘Mild’, ‘Moderate’, ‘Se-  
vere’) using ‘Normal’ as the reference. Only complete cases of  
training data available for that marker were considered, i.e. we  
did not include data for variables marked ‘Test not taken’.

### *Analysis Using All Valid Biomarker Data*

After individual biomarker evaluation, logistic regression  
models considering all valid biomarkers (Results Section c) and  
demographic variables were fit to the data. Their predictions  
were tested via internal and external validation using cross-  
validation procedures, additionally we fit models that used all  
available training data. The models include a standard logistic  
regression, a logistic regression regularised with LASSO, and  
two Bayesian models using a flat and a horseshoe prior [22].  
LASSO and Bayesian horseshoe prior models (with projective  
prediction) and regularization constraints that push models to  
converge on sparse solutions with most coefficients near zero,  
and lend themselves to variable reduction as discussed in the  
Reduced Variable Models Section c.

### *Analysis Using Reduced Variable Models*

While a model using all biomarker data may have strong  
predictive power, it is clinically desire-able to have a strong  
prediction with the least amount of biomarkers possible to save  
on resources devoted to biomarker collection. We used two  
methodologies to choose reduced variable models to predict  
COVID-19 severe outcomes, LASSO and Bayesian Projective  
Prediction.

LASSO is an optimization constraint that shrinks parame-  
ters according to their variance, reduces over-fitting, and en-  
ables variable selection [18]. The optimal degree of regulari-  
sation is determined for each cross-by identifying a tuning pa-  
rameter  $\lambda$  within a LASSO specific inner loop of each cross-  
validation step. LASSO has a drawback of having biased coef-  
ficient and log-odds estimates, as such after evaluating LASSO  
models we run a final ‘LASSO inspired’ standard GLM model.

To evaluate LASSO coefficient estimates, we performed re-  
peated nested cross-validation (5-folds the for the inner LASSO  
loop; 5-folds for the outer loop, and 20 repeats).

For a particular dataset fit, LASSO optimises for a sparse  
representation with many coefficients close to zero. Across  
cross-validated trials these variables will vary. LASSO fits are  
statistically biased and are better suited as a guide for vari-  
able selection in a reduced variable standard GLM. As recom-  
mended in Heinze et al [23], we consider the frequency of how

Biomarker	Abbreviation	Place Recorded / Reason	No. of Readings	% of Patients	Reference Range/ Criteria	Clinical Categories	Criteria Description
<b>Blood Clotting Tests</b>							
Activated partial thromboplastin time	APTT	Admission	422	50%	Normal between 21-33 seconds	Normal, Abnormal	Normal: <33; Mild: 33-49.5; Moderate: 49.5-82.5; Severe: >82.5
Prothrombin Time	PT	Admission	435	52%	Normal between 9.5-13 seconds	Normal, Abnormal	Abnormal: >=13
<b>Blood Gas Tests</b>							
Carbon Dioxide	CO2	Arterial/ Point of care	154	18%	Normal: 4.6-6.4 seconds	Normal, Abnormal	Abnormal if outside range
Lactate	pocTLAC	Arterial/ Point of care	154	18%	0.5-2.2 mmol/L	Normal, Abnormal	Abnormal if <0.5 or >2.2
Oxygen	O2	Arterial/ Point of care	154	18%	11.0-14.4 seconds	Normal, Abnormal	Abnormal if <11 or >14.4
Bicarbonate Excess	BE	Arterial or Venous / Point of care	418	50%	22-29	Normal, Abnormal	Abnormal if outside range
pH acid/base scale	pH	Arterial or Venous / Point of care	417	49%	7.35-7.45	Normal, Abnormal	Abnormal if outside these bounds
<b>Coinfection Battery</b>							
Blood Culture	bc_coinfection	Admission	843	100%	34 bacterial strains tested	Positive, Negative	Positive if one or more positive
Respiratory	resp_coinfection	Admission	843	100%	34 bacterial strains tested	Positive, Negative	Positive if one or more positive
Urine	urine_coinfection	Admission	843	100%	34 bacterial strains tested	Positive, Negative	Positive if one or more positive
Viral	viral_coinfection	Admission	843	100%	10 viral infections tested	Positive, Negative	Positive if one or more positive
<b>Diabetes</b>							
Glucose	Glucose	Point of Care / Record Often Not Digitized	222	26%	Non-fasting: 3.0-7.8 mmol/L	Normal, Abnormal	Abnormal if outside range
<b>Full Blood Count Tests</b>							
Hemoglobin	HB	Admission	772	92%	Male 130-170 g/L, Female 120-150 g/L	Normal, Mild, Moderate, Severe	Normal: >gender specific criteria; Mild: 100 to gender specific criteria; Moderate: 80-100; Severe: <80
Platelet Count	PLT	Admission	770	91%	150-450 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal: >150; Mild: 100-150; Moderate: 50-100; Severe: <50
Lymphocytes	Lymphocyte	Admission	772	92%	1.5-4.5 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal 1.5-4.5; Mild 1-1.5; Moderate 0.5-1; Severe: <0.5 or >4.5
Neutrophils	Neutrophil	Admission	772	92%	2.0-7.5 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal 2-7.5; Mild 1-2; Moderate: 0.5-1; Severe: <0.5 or > 7.5
Neutrophil - Lymphocyte Ratio	NLR	Admission	772	92%	0.78 and 3.53	Normal, Mild, Moderate, Severe	Normal: <3; Mild: 3-8; Moderate: 8-18; Severe: >18
White Cell Count	WCC	Admission	772	92%	4.0-11.0 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal: 4-11; Mild: 1-4; Moderate: 0.5-1; Severe: <0.5 and >11
<b>Urea &amp; Electrolytes Tests</b>							
C-Reactive Protein	CRP	Admission	759	90%	< 6 mg/L	Normal, Abnormal	Abnormal if greater than criteria
Estimated Glomerular	eGFR	Admission	707	84%	>90	Normal, Abnormal	Abnormal if greater than criteria
Urea	urea	Admission	754	89%	2.5-7 10 <sup>9</sup> /L	Normal, Abnormal	Abnormal if outside these bounds
<b>Investigatory Tests</b>							
Brain / B-type natriuretic peptide	BNP	Cardiac Function	47	6%	Men under 70: <100pg/ml, Women under 70: <150 pg/ml, All 70yr and over: <300 pg/ml	Normal, Abnormal	Abnormal if greater than age/gender specific criteria
D-Dimer	DDM		111	13%	Age (Years) D-dimer (ng/ml) <60 <500 61-70 <600 71-80 <700 81-90 <800 >90 <900	Normal, Abnormal	Abnormal if greater than age-specific criteria
Ferritin	FER		115	14%	Male: 33-490, Female(0-44): 15-445, Female(45+yr): 30-470	Normal, Mild, Moderate, Severe	Normal: <age/gender appropriate criteria; Mild: >criteria-735; Moderate: 735-2450; Severe: >2450
Fibrinogen	fib		104	12%	1.8-4.0 g/L	Normal, Mild, Severe.	Normal: >1.8; Mild: 1-1.8; Severe: <1
Glycated haemoglobin	HBA1c	Diabetes	17	2%	>=48 mmol/mol	Normal, Abnormal	Abnormal if greater than criteria
Lactate dehydrogenase	LDH	Investigatory	66	8%	240-480 IU/L	Normal, Mild, Moderate, Severe	Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440
Procalcitonin	PCT	ITU / Bacterial Infection	39	5%	Normal range: <0.2ng/mL	Normal, Abnormal	Abnormal: >=0.2
Triglycerides	trig	Investigatory	19	2%	0.5-1.7 mmol/L	Normal, Abnormal	Abnormal if outside these bounds
Troponin-T	trop	Cardiac Function	177	21%	Normal: <14ng/L	Normal, Abnormal	Abnormal if greater than criteria
<b>Covid-19 Test</b>							
Covid CT	Covid CT		843	100%	Threshold unique to type of test. Lab reports categorical 'positive' variable alongside CT value	Positive, Negative	Only positives included in current study
<b>Other Data</b>							
Age	Age		843	100%		Continuous	All ages >=18
Gender	Gender		843	100%		Male, Female	
Covid Positive on Admission	OnAdmission		843	100%		True, False	Tested only in univariate evaluation
Outcome	Outcome		843	100%		Discharge, ICU, Death	

Figure 2: Variables recorded in the LabMarCS dataset, including plain text description, abbreviation, place of record, frequency in the dataset, and criteria used for converting continuous readings into categorical values.




Figure 3: Example a single patient's time series laboratory biomarker data. See Figure 2 for biomarker abbreviations. Biomarker results are normalised to span 0 to 1 via offsetting by the absolute value of the minimum value and dividing by the maximum value.




Figure 4: Example distribution of biomarker readings for Neutrophil Training and Validation Data. Vertical lines indicate clinical thresholds for bounds on Normal, Mild, Moderate, and Severe categorization.

186 often a particular biomarker has a coefficient greater than zero  
187 and count across cross-validation trials.

188 For a 'LASSO inspired' reduced variable standard GLM, it  
189 was chosen that if at least one categorical level for a particular  
190 biomarker (e.g. 'Severe') met this requirement, all levels for  
191 that biomarker were included in the model. This resulted in a  
192 final set of variables that could then fit with standard logistic  
193 GLM.

194 The second variable selection method explored was Bayesian  
195 projective prediction [19], a technique for constructing an optimal  
196 reference model (in our case a Bayesian logistic regression with a  
197 horseshoe prior /citecarvalho2009handling over the distribution of  
198 coefficient values) that generates a ranking of individual variable  
199 informativeness via leave-one-out (LOO) cross-validation. This  
200 ranking of variables can be used to create a projection model where  
201 one can arbitrarily remove variables post-hoc. This approach allows  
202 one to evaluate the trade-off between AUC performance and the number  
203 of variables included in the model and use a reduced model projection  
204 at a desired AUC cutoff. Bayesian methods have the benefit of allowing  
205 coefficient shrinkage via the horseshoe prior and provide unbiased  
206 odds estimates. Further projective prediction allows the flexibility  
207 to train one model on all valid available data, perform variable  
208 selection, and then use any projected sub-model with reduced variables  
209 to predict outcomes for novel data.  
210

## 211 Results

### 212 Cohort Description

213 The initial cohort included 1159 patients which was narrowed  
214 down to 843 patients who met all inclusion criteria described above,  
215 see Figure 1. 57% of patients were hospitalised for COVID-19 and  
216 the remainder had nosocomial infection. For our statistical models,  
217 the training cohort (n=590) was defined as all adults admitted to  
218 hospital and testing positive for SARS-Cov-2 by PCR, or testing  
219 positive while already admitted between March and October 2020.  
220 For external validation, we held the DGH cohort (n=253) out of  
221 training. Figure 5 depicts the distribution of ages and genders in  
222 the training and validation data sets. Patients in the training set  
223 had a mean age of 70, were 44% female, and 29% had severe  
224 outcomes. The validation set had a mean age of 75, were 47%  
225 female, and 38% had a severe outcome.  
226

### 227 Prediction Using Individual Variables

228 Figure 6 shows descriptive statistics on individual biomarker  
229 readings and their odds ratio contributions in a 5-fold 20-repeat  
230 cross-validated logistic regression including the particular biomarker  
231 and age and gender. Figure 7 details performance using the area  
232 under the receiver operating characteristic curve (AUC) metric,  
233 comparing biomarker models (a particular biomarker plus age and  
234 gender) to a model using only age and gender. Due to the categorical  
235 representation of the biomarkers, individual levels may be significant  
236 while another is not (e.g. 'Severe' is a predictor, but 'Mild' is  
237 not). Statistically significant predictors (i.e. odds ratios deviating  
238 from one with p-value at




Figure 5: Distribution of age and gender for hospitalized patients with coronavirus disease 2019 (COVID-19) for (Top) training data (n=590) and (Bottom) hold out validation data (n=253) cohorts.

using all valid training data (n=590) and testing on the same data (internal validation) and testing on the held out external validation data (n=253).

Models trained on the full data have improved AUC scores, but do not provide a direct uncertainty estimate, this could be done via bootstrapping for a single model, but we instead compute inter-quantile ranges across 5-fold 20 repeat cross-validation models. Cross-validation results provide 95% inter-quantile ranges that clearly illustrate that in general, all models perform similarly, with a median AUC in the mid 0.70's in internal validation, and near the high 0.60's in external validation. There is a trend for the models that encourage sparse representations, LASSO and Bayes with horseshoe prior, to have slightly higher AUC's coupled with higher sensitivity and lower specificity. The calibration of the models is reasonably good on the full data, all training data, but has poor calibration on the validation set, see Supplementary Figure S9.

### Reduced Variable Models

The models detailed above are moderately good predictors of severe COVID-19 outcomes, but for clinicians with limited time and resources, reduced models can balance predictive performance with ease of clinical use by using only the most informative biomarkers. To address this, we use two variable selection approaches, LASSO and projective prediction, that allow the creation of reduced models with fewer biomarkers but similar performance to the larger models.

### LASSO Models

After performing 5-fold 20 repeat cross-validation we examined the frequency of how often a particular biomarker has a coefficient greater than zero and count across cross-validation trials. Figure S10 shows the frequency of variables having a coefficient great than zero in the cross-validated LASSO analysis. If we select variables that appear at least 50% of the time, our reduced model would include: Age, CRP (abnormal), FER (mild), FIB (mild), HB (severe), PLT (mild, moderate, severe), Lymphocytes (Severe), Neutrophils (Mild, Severe), NLR (Severe), APTT (mild, moderate), PT (abnormal), blood pH (abnormal), Urea (abnormal), and positive viral and blood culture co-infections.

For a 'LASSO inspired' reduced variable standard GLM, this resulted in a model using the 15 biomarkers above for all categorical levels, and was evaluated via both cross-validation and as fit to all available training data. This model had performance very similar to the models using all valid biomarker data, with a median external validation AUC of 0.68 [0.63, 0.72], see Figures 8 and 9.

Note, 'Test Not Taken' is a significant predictor for LDH and Lactate on over 50% of cross-validation trials. The potential significance of missing data is complex and is addressed in the Discussion Section. Due to this confounding, biomarkers whose top predictive contribution was from 'Test Not Taken' were excluded from both LASSO reduced variable models and projective prediction models described below.

0.05 or lower) associated with increasing risk of a severe outcome (as shown in Figure 6) include age, and the biomarkers: Activated Partial Thromboplastin Time (Mild), Prothrombin time (Abnormal), blood pH (Abnormal), Haemoglobin (Severe), Platelet count (Moderate), Lymphocytes (Moderate, Severe), Neutrophils (Severe), Neutrophil-Lymphocyte Ratio (Mild, Moderate, Severe), C-Reactive Protein (Abnormal), Urea (Abnormal), and Troponin-T (Abnormal). Nosocomial transmission was included due to the high number of cases in our cohort but was not a significant predictor and excluded from further analyses. Due to small numbers preventing cross validation, Triglycerides, Glycated Haemoglobin, and Procalcitonin (also invalid due to being recorded only in ICU) were excluded from further analysis and require future research.

### Regression Models Using All Valid Biomarker Data

Each model was evaluated via 5-fold cross-validation with 20 repeats (100 models total). As such, each model is trained with a randomised sample of 80% of the training data set (n=472), Internal validation evaluates a model predictions on the 20% (n=118) held out. External validation uses the same model, but is instead tested on the held out validation data set (n=253). Missing data for each biomarker is coded as 'Test Not Taken' and is included as a predictor variable. Figure 8 shows the performance of these models (AUC, Sensitivity, Specificity). For comparison, Figure 9 shows the performance of each model

Biomarker	Binary Categorical Variable	% of Patients with Biomarker Recording	# TRUE (% of TRUE Observations with Severe Outcome)	# FALSE (% of FALSE Observations with Severe Outcome)	Standard Logistic GLM		Bayesian Logistic (Flat Prior)	Bayesian Logistic (Horse Shoe Prior)
					P Value	Odds Ratio [2.5%, 97.5%]	Odds Ratio [2.5%, 97.5%]	Odds Ratio [2.5%, 97.5%]
<b>Demographics / Other</b>								
Age	-	100%	-	-	3.22E-05	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]
Gender	Female	100%	257 (26%)	333 (32%)	0.08	0.72 [0.50, 1.03]	0.72 [0.50, 1.03]	0.79 [0.54, 1.06]
Age & Gender	-	100%	-	-	2.83E-05	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]
	Female							
Nosocomial Transmission	TRUE	100%	240 (30%)	350 (29%)	0.65	0.92 [0.63, 1.33]	0.92 [0.63, 1.33]	0.98 [0.74, 1.19]
<b>Blood Clotting Tests</b>								
Activated partial thromboplastin time	Mild	54%	30 (63%)	291 (320%)	2.44E-03	3.44 [1.57, 7.88]	3.44 [1.55, 7.86]	2.89 [1.12, 6.44]
	Moderate	54%	4 (100%)	317 (34%)	0.98	9.91E+06 [0.00, NA]	4.4E+104 [5.4E+04, Inf]	7.86 [0.92, 464.23]
Prothrombin Time	Abnormal	56%	45 (58%)	288 (31%)	2.96E-03	2.73 [1.41, 5.36]	2.79 [1.44, 5.37]	2.26 [1.01, 4.63]
<b>Blood Gas Tests</b>								
Carbon Dioxide	Abnormal	21%	68 (59%)	57 (51%)	0.33	1.44 [0.70, 2.99]	1.46 [0.72, 3.02]	1.08 [0.82, 1.95]
Lactate	Abnormal	21%	13 (54%)	112 (55%)	0.96	1.03 [0.32, 3.44]	1.04 [0.33, 3.40]	1.02 [0.61, 1.80]
Oxygen	Abnormal	21%	105 (55%)	20 (55%)	0.98	1.01 [0.38, 2.66]	1.00 [0.37, 2.68]	0.99 [0.63, 1.53]
Bicarbonate Excess	Abnormal	64%	123 (38%)	252 (31%)	0.26	1.30 [0.82, 2.05]	1.31 [0.84, 2.04]	1.09 [0.87, 1.65]
pH acid/base scale	Abnormal	63%	136 (46%)	238 (26%)	1.05E-04	2.45 [1.56, 3.87]	2.48 [1.58, 3.97]	2.19 [1.34, 3.53]
<b>Coinfection</b>								
Blood Culture	TRUE	100%	5 (0%)	585 (30%)	0.98	3.20E-07 [NA, 2.94E+22]	0 [0, 0]	0.42 [0.02, 1.40]
Respiratory	TRUE	100%	6 (50%)	584 (29%)	0.20	2.95 [0.52, 16.62]	2.96 [0.46, 18.46]	1.23 [0.70, 4.76]
Urine	TRUE	100%	12 (25%)	579 (30%)	0.63	0.72 [0.15, 2.53]	0.63 [0.13, 2.56]	0.94 [0.38, 2.03]
Viral	TRUE	100%	7 (71%)	583 (29%)	0.06	4.95 [1.04, 35.13]	5.93 [1.01, 45.18]	1.82 [0.83, 10.36]
<b>Diabetes</b>								
Glucose	Abnormal	30%	49 (45%)	126 (32%)	0.11	1.77 [0.88, 3.54]	1.77 [0.88, 3.56]	1.28 [0.88, 2.63]
<b>Full Blood Count Tests</b>								
Hemoglobin	Mild	92%	176 (36%)	368 (27%)	0.13	1.38 [0.91, 2.08]	1.38 [0.91, 2.10]	1.13 [0.90, 1.72]
	Moderate		48 (33%)	495 (30%)	0.62	1.19 [0.59, 2.29]	1.18 [0.59, 2.30]	1.02 [0.71, 1.61]
	Severe		11 (55%)	532 (30%)	0.03	4.08 [1.16, 15.06]	4.26 [1.17, 16.54]	1.57 [0.82, 6.68]
Platelet Count	Mild	92%	67 (39%)	474 (29%)	0.07	1.65 [0.95, 2.83]	1.64 [0.95, 2.79]	1.32 [0.90, 2.30]
	Moderate		17 (65%)	524 (29%)	0.01	4.21 [1.54, 12.65]	4.42 [1.59, 13.10]	2.58 [0.96, 8.72]
	Severe		4 (75%)	537 (30%)	0.12	6.16 [0.76, 126.83]	9.29 [0.82, 245.54]	1.77 [0.65, 14.71]
Lymphocytes	Mild	92%	151 (27%)	392 (31%)	0.12	1.69 [0.89, 3.34]	1.70 [0.87, 3.35]	1.10 [0.76, 1.98]
	Moderate		217 (31%)	326 (30%)	0.03	1.96 [1.07, 3.75]	1.99 [1.08, 3.81]	1.22 [0.88, 2.26]
	Severe		84 (48%)	459 (27%)	4.99E-04	3.48 [1.75, 7.17]	3.53 [1.75, 7.20]	2.08 [1.00, 4.34]
Neutrophils	Mild	92%	23 (13%)	520 (31%)	0.23	0.47 [0.11, 1.43]	0.40 [0.09, 1.35]	0.76 [0.26, 1.32]
	Moderate		3 (33%)	540 (30%)	0.67	1.71 [0.08, 19.15]	1.27 [0.03, 21.43]	1.01 [0.28, 3.66]
	Severe		143 (41%)	400 (26%)	1.88E-03	1.92 [1.27, 2.91]	1.94 [1.28, 2.89]	1.72 [1.08, 2.71]
Neutrophil - Lymphocyte Ratio	Mild	92%	237 (28%)	306 (32%)	3.69E-03	2.50 [1.38, 4.79]	2.57 [1.39, 4.98]	1.84 [0.99, 3.50]
	Moderate		137 (39%)	406 (27%)	3.18E-05	3.97 [2.12, 7.81]	4.13 [2.19, 8.29]	2.92 [1.44, 5.76]
	Severe		54 (54%)	489 (28%)	2.61E-06	6.38 [2.99, 14.14]	6.69 [3.13, 15.02]	4.52 [1.99, 10.44]
White Cell Count	Mild	92%	57 (23%)	486 (31%)	0.34	0.71 [0.36, 1.38]	0.71 [0.36, 1.37]	0.86 [0.46, 1.23]
	Moderate		2 (50%)	541 (30%)	0.45	3.03 [0.11, 83.24]	3.08 [0.08, 122.91]	1.14 [0.42, 4.94]
	Severe		85 (42%)	458 (28%)	0.02	1.84 [1.12, 3.00]	1.84 [1.12, 3.02]	1.50 [0.96, 2.77]
<b>Urea &amp; Electrolytes Tests</b>								
C-Reactive Protein	Abnormal	91%	489 (33%)	47 (4%)	1.49E-03	10.23 [3.08, 63.44]	13.12 [3.39, 87.29]	7.45 [2.52, 33.50]
Estimated Glomerular Filtration Rate	Abnormal	82%	350 (38%)	131 (18%)	0.06	1.76 [0.98, 3.23]	1.80 [0.99, 3.31]	1.38 [0.88, 2.70]
Urea	Abnormal	89%	262 (47%)	264 (15%)	4.23E-11	4.27 [2.79, 6.63]	4.33 [2.82, 6.73]	4.09 [2.67, 6.41]
<b>Investigatory Tests</b>								
Brain / B-type natriuretic peptide	Abnormal	7%	30 (53%)	14 (29%)	0.13	3.91 [0.73, 27.00]	4.65 [0.77, 31.41]	1.53 [0.73, 8.01]
D-Dimer	Abnormal	12%	52 (42%)	18 (33%)	0.67	1.29 [0.40, 4.43]	1.32 [0.40, 4.79]	1.08 [0.59, 2.48]
Ferritin	Mild	14%	11 (64%)	72 (39%)	0.09	3.61 [0.84, 17.70]	4.17 [0.88, 20.84]	1.30 [0.81, 4.78]
	Moderate	14%	28 (46%)	55 (40%)	0.27	1.79 [0.64, 5.15]	1.87 [0.63, 5.55]	1.10 [0.72, 2.38]
	Severe	14%	6 (33%)	77 (43%)	0.94	0.93 [0.11, 5.90]	0.85 [0.10, 5.65]	0.94 [0.36, 1.70]
Fibrinogen	Mild	5%	4 (75%)	26 (46%)	0.10	11.27 [0.85, 360.85]	25.22 [1.14, 1.05E+03]	1.44 [0.08, 9.96]
	Severe	5%	3 (67%)	27 (48%)	0.40	3.41 [0.23, 105.85]	5.42 [0.21, 308.55]	1.11 [0.46, 4.62]
Glycated haemoglobin*	Abnormal	3%	11 (9%)	4 (0%)	1.00	2.98E+08 [0, NA]	2.2E+07 [0.23, 1.3E+39]	1.42 [0.36, 22.68]
Lactate dehydrogenase	Mild	6%	12 (67%)	25 (56%)	0.49	2.61 [0.19, 71.00]	3.93 [0.18, 134.47]	1.14 [0.59, 3.50]
	Moderate	6%	16 (63%)	21 (57%)	0.78	1.49 [0.10, 40.47]	1.90 [0.08, 64.73]	1.00 [0.41, 2.27]
	Severe	6%	5 (60%)	32 (59%)	0.34	4.63 [0.22, 178.20]	8.20 [0.25, 502.08]	1.08 [0.43, 3.96]
Procalcitonin*	Abnormal	4%	21 (86%)	4 (100%)	1.00	1.15E-07 [NA, 1.6E+184]	3.2E-08 [3.07E-39, 7.82]	0.80 [0.08, 2.84]
Triglycerides*	Abnormal	3%	10 (90%)	5 (100%)	1.00	1.68E-09 [NA, Inf]	2.1E-06 [5.62E-26, 1.46]	0.75 [0.05, 2.88]
Troponin-T	Abnormal	24%	91 (44%)	51 (22%)	0.03	2.96 [1.17, 7.96]	3.09 [1.17, 8.48]	1.75 [0.94, 4.94]

\* Biomarkers not included in subsequent models due to small sample size, and recorded only in ICU (PCT)

Figure 6: Individual biomarker evaluation including descriptive statistics and logistic regression model outcomes (Standard, Bayesian with flat prior, and Bayes with horseshoe prior), including age and gender (except univariate age and gender models). Regressions were fit using all associated dummy variables for a given biomarker (e.g. normal, mild, moderate, severe) and using only complete cases of training data, i.e. not using a variable for 'Test not taken.' Categorical variables use a reading of 'Normal' as a reference in the fitted model, except 'Male' used as the reference category for gender.

Demographic / Biomarker	Standard Logistic GLM		Bayesian Logistic (Flat Prior)		Bayesian Logistic (Horse Shoe Prior)	
	Cross-Validated 80/20 Split		Cross-Validated 80/20 Split		Cross-Validated 80/20 Split	
	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]
<b>Demographics / Other</b>						
Age	0.62 [0.48, 0.71]	0.00, [-0.11, 0.04]	0.62 [0.46, 0.71]	0.00 [-0.10, 0.07]	0.62 [0.45, 0.70]	0.00 [-0.06, 0.09]
Gender	0.55 [0.45, 0.63]	0.08, [-0.05, 0.17]	0.56 [0.48, 0.64]	0.05 [-0.08, 0.14]	0.55 [0.44, 0.63]	0.07 [-0.14, 0.21]
Age & Gender	0.61 [0.50, 0.72]	0.00, [0.00, 0.00]	0.61 [0.48, 0.72]	0.00 [-0.02, 0.02]	0.61 [0.45, 0.72]	0.00 [-0.03, 0.02]
Nosocomial Transmission	0.61 [0.46, 0.73]	0.00, [-0.01, 0.05]	0.61 [0.48, 0.73]	0.00 [-0.02, 0.04]	0.61 [0.46, 0.72]	0.00 [-0.07, 0.02]
<b>Blood Clotting Tests</b>						
Activated partial thromboplastin time	0.66 [0.45, 0.78]	-0.05, [-0.22, 0.04]	0.66 [0.45, 0.78]	-0.04 [-0.23, 0.04]	0.65 [0.45, 0.75]	-0.05 [-0.20, 0.05]
Prothrombin Time	0.64 [0.50, 0.76]	-0.03 [-0.15, 0.05]	0.64 [0.50, 0.76]	-0.03 [-0.15, 0.05]	0.63 [0.44, 0.76]	-0.03 [-0.13, 0.05]
<b>Blood Gas Tests</b>						
Carbon Dioxide	0.56 [0.40, 0.76]	0.01 [-0.13, 0.15]	0.55 [0.43, 0.76]	0.02 [-0.18, 0.17]	0.55 [0.44, 0.74]	0.02 [-0.20, 0.18]
Lactate	0.57 [0.44, 0.79]	0.00 [-0.09, 0.19]	0.58 [0.40, 0.75]	-0.01 [-0.24, 0.17]	0.55 [0.37, 0.81]	0.00 [-0.25, 0.16]
Oxygen	0.56 [0.44, 0.78]	0.00 [-0.18, 0.11]	0.56 [0.43, 0.77]	0.00 [-0.16, 0.13]	0.58 [0.45, 0.75]	0.00 [-0.21, 0.14]
Bicarbonate Excess	0.58 [0.43, 0.71]	0.00 [-0.12, 0.14]	0.58 [0.42, 0.71]	0.00 [-0.17, 0.16]	0.60 [0.44, 0.70]	0.00 [-0.07, 0.11]
pH acid/base scale	0.64 [0.43, 0.75]	-0.05 [-0.22, 0.10]	0.64 [0.45, 0.75]	-0.06 [-0.22, 0.09]	0.64 [0.46, 0.75]	-0.05 [-0.16, 0.08]
<b>Coinfection</b>						
Blood Culture	0.62 [0.46, 0.73]	-0.01 [-0.02, 0.00]	0.62 [0.48, 0.73]	-0.01 [-0.03, 0.01]	0.62 [0.47, 0.72]	0.00 [-0.02, 0.02]
Respiratory	0.61 [0.49, 0.73]	0.00 [-0.02, 0.02]	0.62 [0.50, 0.74]	0.00 [-0.04, 0.02]	0.62 [0.47, 0.72]	0.00 [-0.02, 0.03]
Urine	0.61 [0.49, 0.71]	0.00 [-0.01, 0.02]	0.61 [0.47, 0.71]	0.00 [-0.02, 0.03]	0.62 [0.46, 0.72]	0.00 [-0.02, 0.02]
Viral	0.62 [0.43, 0.71]	0.00 [-0.01, 0.01]	0.62 [0.44, 0.71]	0.00 [-0.03, 0.05]	0.62 [0.46, 0.71]	0.00 [-0.03, 0.02]
<b>Diabetes</b>						
Glucose	0.61 [0.45, 0.78]	-0.02 [-0.10, 0.14]	0.61 [0.47, 0.78]	-0.02 [-0.09, 0.09]	0.61 [0.45, 0.78]	-0.01 [-0.21, 0.12]
<b>Full Blood Count Tests</b>						
Hemoglobin	0.62 [0.48, 0.71]	-0.01 [-0.05, 0.04]	0.62 [0.49, 0.71]	-0.01 [-0.05, 0.05]	0.62 [0.48, 0.71]	0.00 [-0.04, 0.03]
Platelet Count	0.64 [0.48, 0.74]	-0.01 [-0.07, 0.06]	0.64 [0.52, 0.74]	-0.02 [-0.06, 0.05]	0.64 [0.46, 0.74]	-0.01 [-0.12, 0.06]
Lymphocytes	0.65 [0.55, 0.73]	-0.04 [-0.10, 0.04]	0.65 [0.55, 0.73]	-0.04 [-0.10, 0.05]	0.64 [0.52, 0.72]	-0.02 [-0.07, 0.02]
Neutrophils	0.63 [0.55, 0.72]	-0.02 [-0.12, 0.06]	0.63 [0.53, 0.72]	-0.02 [-0.08, 0.07]	0.63 [0.54, 0.72]	-0.03 [-0.19, 0.05]
Neutrophil - Lymphocyte Ratio	0.67 [0.57, 0.76]	-0.06 [-0.16, 0.06]	0.67 [0.57, 0.77]	-0.06 [-0.15, 0.06]	0.67 [0.56, 0.76]	-0.06 [-0.11, 0.04]
White Cell Count	0.62 [0.48, 0.72]	0.00 [-0.09, 0.08]	0.62 [0.48, 0.72]	0.00 [-0.08, 0.08]	0.62 [0.46, 0.74]	-0.01 [-0.05, 0.08]
<b>Urea &amp; Electrolytes Tests</b>						
C-Reactive Protein	0.65 [0.45, 0.74]	-0.03 [-0.08, 0.03]	0.65 [0.44, 0.74]	-0.03 [-0.09, 0.04]	0.65 [0.44, 0.74]	-0.04 [-0.15, 0.05]
Estimated Glomerular Filtration Rate	0.62 [0.53, 0.71]	-0.01 [-0.03, 0.04]	0.62 [0.52, 0.71]	-0.01 [-0.04, 0.04]	0.62 [0.51, 0.71]	0.00 [-0.04, 0.05]
Urea	0.71 [0.59, 0.80]	-0.09 [-0.18, -0.02]	0.71 [0.59, 0.80]	-0.09 [-0.19, -0.01]	0.71 [0.59, 0.81]	-0.09 [-0.20, -0.01]
<b>Investigatory Tests</b>						
Brain / B-type natriuretic peptide	0.67 [0.44, 0.94]	-0.05 [-0.33, 0.25]	0.67 [0.45, 0.94]	0.00 [-0.33, 0.22]	0.65 [0.40, 0.94]	0.00 [-0.33, 0.25]
D-Dimer	0.62 [0.44, 0.85]	0.01 [-0.15, 0.24]	0.63 [0.43, 0.83]	0.00 [-0.21, 0.22]	0.65 [0.42, 0.89]	0.00 [-0.10, 0.17]
Ferritin	0.61 [0.44, 0.83]	-0.01 [-0.26, 0.21]	0.61 [0.45, 0.83]	0.00 [-0.29, 0.20]	0.58 [0.43, 0.80]	-0.01 [-0.31, 0.20]
Fibrinogen	0.67 [0.38, 1.00]	0.00 [-0.44, 0.50]	0.75 [0.38, 1.00]	0.00 [-0.40, 0.44]	0.75 [0.38, 1.00]	0.00 [-0.44, 0.33]
Glycated haemoglobin*	NA	NA	NA	NA	NA	NA
Lactate dehydrogenase	0.67 [0.40, 1.00]	0.00 [-0.42, 0.33]	0.67 [0.40, 1.00]	0.00 [-0.42, 0.40]	0.67 [0.30, 1.00]	0.00 [-0.25, 0.25]
Procalcitonin*	NA	NA	NA	NA	NA	NA
Triglycerides*	NA	NA	NA	NA	NA	NA
Troponin-T	0.57 [0.40, 0.77]	-0.01 [-0.22, 0.20]	0.57 [0.40, 0.76]	-0.01 [-0.25, 0.18]	0.59 [0.43, 0.78]	-0.01 [-0.25, 0.13]

\* Biomarkers not included in subsequent models due to small sample size, and recorded only in ICU (PCT)

Figure 7: Predictive performance of the individual biomarker models in Figure 6 as described by the median area under the curve (AUC) in receiver operating curve (ROC) analysis and median difference between an Age and Gender reference model and the same model with the particular biomarker included (except univariate age and gender models). Regressions were fit using all associated dummy variables for a given biomarker (e.g. mild, moderate, severe) and using only complete cases of training data (n=590), i.e. not using a variable for 'Test not taken.' 95% inter-quantile ranges calculated via 5-fold cross-validation with 20 repeats (100 models total). Categorical variables use a reading of 'Normal' as a reference in the fitted model, except 'Male' used as the reference category for gender.



Model	Internal Validation			External Validation		
	AUC [2.5%, 97.5%]	Specificity at 90% Sensitivity [2.5%, 97.5%]	Specificity at 95% Sensitivity [2.5%, 97.5%]	AUC [2.5, 97.5]	Specificity at 90% Sensitivity [2.5%, 97.5%]	Specificity at 95% Sensitivity [2.5%, 97.5%]
<i>Standard Logistic GLM</i>	0.70 [0.64, 0.81]	0.39 [0.04, 0.57]	0.20 [0.00, 0.50]	0.67 [0.61, 0.71]	0.28 [0.16, 0.39]	0.13 [0.01, 0.24]
<i>Standard GLM with LASSO regularisation</i>	0.77 [0.71, 0.86]	0.46 [0.26, 0.60]	0.35 [0.11, 0.52]	0.69 [0.67, 0.71]	0.32 [0.25, 0.40]	0.19 [0.14, 0.27]
<i>Bayesian GLM (Flat Prior)</i>	0.75 [0.67, 0.82]	0.41 [0.02, 0.60]	0.22 [0.00, 0.49]	0.67 [0.63, 0.71]	0.27 [0.18, 0.38]	0.13 [0.01, 0.24]
<i>Bayesian GLM (Horse Shoe Prior)</i>	0.78 [0.71, 0.85]	0.49 [0.32, 0.67]	0.38 [0.16, 0.59]	0.70 [0.68, 0.71]	0.33 [0.29, 0.39]	0.23 [0.18, 0.26]
<i>LASSO inspired GLM (15 biomarkers)</i>	0.76 [0.35, 0.76]	0.43 [0.08, 0.64]	0.25 [0.01, 0.57]	0.68 [0.63, 0.72]	0.28 [0.20, 0.38]	0.13 [0.03, 0.25]
<i>Projective Prediction (28 Biomarkers)</i>	0.78 [0.70, 0.85]	0.50 [0.29, 0.67]	0.37 [0.14, 0.59]	0.70 [0.68, 0.71]	0.34 [0.30, 0.39]	0.24 [0.18, 0.25]
<i>Projective Prediction (3 Biomarkers)</i>	0.74 [0.67, 0.82]	0.38 [0.18, 0.58]	0.24 [0.08, 0.50]	0.70 [0.69, 0.71]	0.38 [0.18, 0.58]	0.24 [0.08, 0.50]

Figure 8: Cross-validated performance of models trained using valid biomarker data. 95% inter-quantile ranges are presented for each estimate. Specificity is obtained by evaluating at a set sensitivity of either 90% or 95%. All reduced variable models include age, and a stated number of biomarkers. The reduced variable LASSO inspired standard GLM uses 15 biomarkers that had non-zero coefficients on  $\geq 50\%$  LASSO Cross-validation trials. If at least one categorical level for a particular biomarker (e.g. severe) met this requirement, all levels for that biomarker were included in the model. The 3 biomarker projective prediction model uses all categorical levels for Urea, PT, and NLR.

Model	Internal Validation					External Validation				
	Accuracy	AUC	Brier	Sensitivity	Specificity	Accuracy	AUC	Brier	Sensitivity	Specificity
<i>Standard Logistic GLM</i>	0.82	0.87	0.13	0.93	0.56	0.66	0.69	0.13	0.82	0.40
<i>Standard GLM with LASSO regularisation</i>	0.77	0.83	0.23	0.94	0.39	0.62	0.69	0.38	0.93	0.13
<i>LASSO inspired GLM (15 biomarkers)</i>	0.79	0.84	0.14	0.91	0.50	0.67	0.69	0.14	0.88	0.34
<i>Bayesian GLM (Flat Prior)</i>	0.82	0.86	0.18	0.92	0.58	0.64	0.68	0.36	0.79	0.40
<i>Bayesian GLM (Horse Shoe Prior)</i>	0.79	0.84	0.21	0.94	0.45	0.63	0.71	0.37	0.89	0.22
<i>Projective Prediction (28 Biomarkers)</i>	0.79	0.83	0.21	0.94	0.44	0.64	0.71	0.36	0.90	0.24
<i>Projective Prediction (3 Biomarkers)</i>	0.73	0.75	0.27	0.91	0.30	0.67	0.70	0.33	0.94	0.24

Figure 9: Performance of models using all valid biomarker data trained on all training data available (n=590). Internal validation is trained on all of the training data and tested on the same. External validation uses the same model and is tested on held out validation data set (n=253). Missing data for each biomarker is coded as 'Test Not Taken'. Specificity and sensitivity evaluated using a probability threshold of 0.5 (i.e. assumes a well-calibrated model). All reduced variable models include age, and a stated number of biomarkers. The reduced variable LASSO inspired standard GLM uses 15 biomarkers that had non-zero coefficients on  $\geq 50\%$  LASSO Cross-validation trials. If at least one categorical level for a particular biomarker (e.g. severe) met this requirement, all levels for that biomarker were included in the model. The 3 biomarker projective prediction model uses all categorical levels for Urea, PT, and NLR.

## Projective Prediction Models

When all biomarkers were considered, projective prediction identifies the following predictors in the top 20, in order of contribution to AUC: Urea (abnormal), Age, PT (abnormal), NLR (Severe), pH (abnormal), Lymphocytes (severe), APPT(mild), eGFR (abnormal), Neutrophils (Severe), APPT(moderate), CRP (abnormal), DDM (abnormal), Hemoglobin (severe). Thus age and 12 biomarkers are candidates for a reduced model. Note, several predictors of 'Test Not Taken' were also selected including Lactate, O<sub>2</sub>, CO<sub>2</sub>, LDH, Ferritin and Fibrinogen. As mentioned above, these biomarkers are set aside due to this confounding. Supplementary Figures S11 and S12 display the output from projective prediction ranking the contribution of each variable to the model. A model using a projection incorporating all biomarker and demographic data is equivalent to the standard Bayesian GLM we evaluated in the prior section, see Figures 8 and 9.

Reduced variable projections were evaluated by manual inspection of AUC performance among groups of models using the top biomarkers. Guided by the projective prediction ranking, we ran a model using only the top biomarker, using only the top two, the top three, and so on. As described above we omit biomarkers with significant contributions from 'Test Not Taken' and include all categorical levels for a given biomarker as long as one level is highly ranked. Ultimately, we found a 3 biomarker projective prediction model using age and including urea, prothrombin time, neutrophil-lymphocyte ratios had similar performance to larger models with a median internal validation AUC of 0.74 [0.67, 0.82], and external validation AUC of 0.70 [0.69, 0.71], as shown in Figures 8 and 9. Odds ratios for the full Bayesian model and the reduced 3-biomarker model can be found in Supplementary Table S13. The calibration of the model is reasonably good on the training data but has poor calibration on the validation set, see Supplementary Figure S14.

## Discussion

### Challenges of Complex Medical Data

Curating the LabMarCS data is challenging as the data are heterogeneous in multiple ways. Biomarkers are recorded for different reasons, e.g. routine upon admission, investigatory tests, or tests primarily or exclusively taken in ICU. Further some biomarkers are typically recorded together (but not always) as part of a test suite, including: Urea and electrolytes, full blood count, COVID-19 and co-infection swab test, blood clotting, and blood gas tests (arterial or venous). The schedule when some these markers are recorded vary by patient and clinical decision, leading to records being present in highly varying amounts, e.g. only 3% up to 100% of patients depending on the particular biomarker, see Supplementary Figure S1.

### Modelling Choices

When constructing and evaluating models, there are many choice points that should be explicitly highlighted with justification, be it based on convenience, computational complexity,

clinical advice, or a heuristic. The space of potential models is vast and most studies will constrain the model search space, delineating why these choices are made will facilitate understanding and reproduction by other researchers. These include key choices relating to: patient inclusion/exclusion criteria, data missingness protocols, data transformations, training and validation data selection, and performance evaluation.

### Missing Data

Missingness, in the context of this study and in healthcare data more generally, can sometimes be informative and missing not at random (MNAR), with the presence or absence of a test correlated with the measurement of said test. Imputation of missing data relies on key statistical assumptions that imputed variables are missing at random (MAR) or missing completely at random (MCAR), else the imputation will be faulty and models may be fit to non-representative data. Conversations with our clinical colleagues established some routinely collected biomarkers might be inferred to be MAR. However, the routines identified were specific to a small subset of our cohort and not likely to extrapolate. We ultimately erred to be conservative and avoid all imputation, and instead include missing values as a data point [24, 25]. As such, in the current study we chose to use placeholders for 'Test not taken' if there was no recorded value for a particular biomarker within the evaluated 3-day window.

This approach however, allows the possibility that a 'Test Not Taken' may be a significant predictor. This has many potential meanings, as it may convey that when a patient is doing well and unlikely to experience a severe outcome, clinicians are unlikely to request some biomarker tests. Alternatively, if a patient is in palliative care and has a poor prognosis, a clinician may consider further testing unnecessary. As such, the likelihood of a test being administered may follow an inverted-U function as patients to healthy or too ill may not have tests administered. Furthermore, as our data was collected early in the pandemic, there may be other underlying clinical decisions or resource limitations that drove why some tests were taken but not others. Lastly, because we only consider results from the first 3 days from a patient's critical date, it may be that some tests are simply taken later in a patient's stay, and hence may be more predictive as they were taken closer to the outcome. Hence, when these instances occurred, we were conservative and excluded biomarkers with 'Test Not Taken' as the most informative category from our reduced variable models.

### Data Transforms - Time Windows

Ideally clinicians can make a decision based on readings the day of admission. However, not all tests are administered on admission. To balance inclusion of test data not available on the day of admission and the need for clinical decisions to be guided soon after admission, we chose to consider the first value recorded for each biomarkers within three days of their 'critical date', i.e. date of admission if already COVID-19 positive, or if already in hospital, the date of testing COVID-19 positive. However, given the richness of the time series data collected,

424 further research into models that leverage this extra information<sup>477</sup>  
425 is needed.<sup>478</sup>

426 Focusing on early detection reflects the intent for the model<sup>479</sup>  
427 to improve early stage clinical decision making when potential<sup>480</sup>  
428 treatments or changes in care may be introduced. This focus<sup>481</sup>  
429 on the first reading in a 3-day interval loses information, but<sup>482</sup>  
430 greatly simplifies the modelling approach. Note, this choice is<sup>483</sup>  
431 not without risk of reducing statistical power, increasing the risk<sup>484</sup>  
432 of false positives, and underestimation of the extent of variation<sup>485</sup>  
433 in biomarker readings and outcomes between groups [26]. It is<sup>486</sup>  
434 likely that representing biomarker data as time series (assuming<sup>487</sup>  
435 regular measures across patients) instead of single points would<sup>488</sup>  
436 add considerable information.

#### 437 *Data Transforms - Continuous vs. Categorical*

438 A key modelling decision must be made on whether to use<sup>491</sup>  
439 continuous data or transformed categorical data. Clinicians of-<sup>492</sup>  
440 ten use biomarker thresholds to provide semantic categories<sup>493</sup>  
441 (e.g. normal, mild, moderate, severe) which sometimes use<sup>494</sup>  
442 non-linear or discontinuous mappings that require special care<sup>495</sup>  
443 if using continuous data. While clinical thresholds are likely<sup>496</sup>  
444 established with evidence, it may be the case that thresholds<sup>497</sup>  
445 for one use may not apply to a novel one. This led [27, 28] to<sup>498</sup>  
446 use machine learning approaches to build categorisation models<sup>499</sup>  
447 on continuous biomarker data dependent on the training data at  
448 hand. However, using machine learning to establish categorisa-<sup>500</sup>  
449 tion thresholds on our biomarker data is difficult with a small<sup>501</sup>  
450 training data set and the heterogeneity of biomarker recordings.<sup>502</sup>  
451 If missing data imputation is done, it raises another decision<sup>503</sup>  
452 point on whether to impute the continuous or the transformed<sup>504</sup>  
453 categorical data.

454 Another important factor to recognise is that some biomark-<sup>505</sup>  
455 ers lack a linear relationship between a reading and a seman-<sup>506</sup>  
456 tic category. Biomarkers can have a lower and upper bound<sup>507</sup>  
457 for what is considered normal, and both below and above this<sup>508</sup>  
458 range reflects clinically meaningful yet sometimes separate ab-<sup>509</sup>  
459 normalities. This means modelling needs to factor in non-linear<sup>510</sup>  
460 curves if persevering continuous data or trying to map to a cat-<sup>511</sup>  
461 egorical space. In our position, categorical transforms had the<sup>512</sup>  
462 advantage as we were able to collaborate with ICU consultants<sup>513</sup>  
463 in conjunction with using pre-established clinically acceptable<sup>514</sup>  
464 ranges defined our categorisation, see Figure 2.<sup>515</sup>

#### 465 *Training and Validation Data Selection*

466 There are multiple ways that our data set could be split be-<sup>517</sup>  
467 tween training and validation sets, e.g. randomly sampling 1/3<sup>518</sup>  
468 of the data to hold out as a validation set. Given our rather<sup>519</sup>  
469 small sample, random selection of training data should in prin-<sup>520</sup>  
470 ciple generate data more representative of the validation set left<sup>521</sup>  
471 out. However, realistically hospitals may have differing prac-<sup>522</sup>  
472 tices and randomization of may inflate performance at the cost<sup>523</sup>  
473 of real world validity. We chose to separate our training and<sup>524</sup>  
474 validation datasets by hospital to provide a stronger test of gen-<sup>525</sup>  
475 eralisation that should mimic generalisation to novel hospitals<sup>526</sup>  
476 completely outside the original training data .<sup>527</sup>

#### *Model Performance Evaluation and Dissemination*

There are a variety of ways statistical model performance  
can be evaluated. Here we have chose here to emphasize cross-  
validated estimates of AUC, sensitivity, and specificity. Inter-  
quartile intervals over these measures reveal that the variety of  
models perform in similar ways. While the full models have  
higher median performance, the reduced models are within the  
95% bounds of the other models. With a larger data set trade-  
offs may become more apparent. Model calibration on the val-  
idation set is a clear weak point. While the models have de-  
cent calibration for training data, generalisation performance is  
weak and suggestive of the lack of sufficient data.

#### 489 *Comparison to Contemporary Models*

Despite our dataset being relatively small, we found several  
biomarkers previously highlighted by other groups to have sig-  
nificant predictive power, including: Urea, Neutrophil-Lymphocyte  
Ratio, Lymphocytes, APTT, eGFR, and CRP. Our highly re-  
duced 3-biomarker model (plus age) uses Urea (highlighted by  
all prior models), Neutrophil-Lymphocyte ratio (highlighted by  
[29, 11, 28]), and APPT (highlighted by [28]). With a larger  
dataset, further vetting of these and other biomarkers would  
be possible, but it gives reassurance that despite our data and  
model limitations, we find similar predictive biomarkers.

#### *Advantages of Bayesian Modelling*

While the predictive performance across models presented  
here is generally quite similar, there are several reasons for re-  
searchers to favor Bayesian approaches. The coefficients esti-  
mated via Bayes should on average deliver slightly better pre-  
dictive performance. Additionally, if a sparse model is needed,  
a horseshoe prior can provide advantages similar to LASSO  
without biased coefficient estimates. Computationally, Bayesian  
techniques can be slow due Markov Chain Monte Carlo used  
to sample the coefficient space. If one is interested in vari-  
able selection, projective prediction offers the ability to take  
a single Bayesian model fit, run a variable selection algorithm  
to rank variable contributions, and then arbitrarily create sub-  
model projections with any number of original variables. While  
the initial model fit and variable selection are computationally  
intensive, sub-model projections are fast to create and perfor-  
mance test.

#### **Summary & Conclusions**

*Limitations:* This is a retrospective cohort study involving a  
relatively small cohort in Southwest England where case num-  
bers have varied widely, and were well below national figures  
during the first wave. This results in less precise parameter es-  
timates for prediction models (less power/smaller sample size)  
and likely reduced generalizability of the model to other set-  
tings. The timing of biomarker collection was highly varied  
both within and between patients, with many types of readings  
missing. While we replicated prior findings on several biomark-  
ers, gender was not significant, suggesting our sample may not  
be representative.

**Strengths:** The primary strength of our study is the granularity of serial laboratory data available linked to clinical outcomes. This study was performed during the first wave where there was the original Wuhan strain circulating amongst the unvaccinated naïve population without any specific immunomodulating therapies such as steroids or antiviral agents, reflecting the “true” homeostasis derangements at a population level.

This study highlights a variety of challenges present in complex medical data sets while maintaining best statistical practices with an emphasis on recent Bayesian methodology. Our study reiterates the predictive value of previously identified biomarkers for COVID-19 severity assessment (e.g. age, urea, prothrombin time, and neutrophil-lymphocyte ratio). Both the full and reduced variable models have moderately good training performance, but improved external validation is needed for all models to be clinically viable. The methods presented here should generalise well to a larger dataset.

## Ethics approval

The study [IRAS project ID: 283439] underwent a rigorous ethical and regulatory approval process, and a favourable opinion was gained from Research Ethics Service, Wales REC 7, c/o Public Health Wales, Building 1, Jobswell Road, St David’s Park, SA31 3HB on 11/09/2020.

## Funding

This work is funded by Health Data Research UK via the Better Care Partnership Southwest (HDR CF0129), Medical Research Council Research Grant MR/T005408/1, and the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund.

## Declaration of competing interest

The authors have no competing interests.

## Acknowledgements

This research was supported by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration West (NIHR ARC West). The views expressed in this article are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

## References

- [1] A. B. Docherty, E. M. Harrison, C. A. Green, H. Hardwick, R. Pius, L. Norman, K. A. Holden, J. M. Read, F. Dondelinger, G. Carson, L. Mereson, J. Lee, D. Plotkin, L. Sigfrid, S. Halpin, C. Jackson, C. Gamble, P. W. Horby, J. S. Nguyen-Van-Tam, I. Investigators, J. Dunning, P. J. M. Openshaw, J. K. Baillie, M. G. Semple, Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol, *medRxiv* (2020) 2020.04.23.20076042 doi: 10.1101/2020.04.23.20076042.
- [2] C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang, X. Zhou, C. Du, Y. Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu, X. Zhou, D. Chen, W. Xiong, L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng, Y. Song, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, *JAMA internal medicine* 180 (7) (2020) 934–943. doi: 10.1001/jamainternmed.2020.0994.
- [3] L. Bowles, S. Platten, N. Yartey, M. Dave, K. Lee, D. P. Hart, V. MacDonald, L. Green, S. Sivapalaratnam, K. J. Pasi, P. MacCallum, Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19, *New England Journal of Medicine* 383 (3) (2020) 288–290. doi: 10.1056/NEJMc2013656.
- [4] N. Tang, D. Li, X. Wang, Z. Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, *Journal of thrombosis and haemostasis: JTH* 18 (4) (2020) 844–847. doi: 10.1111/jth.14768.
- [5] H. Han, L. Yang, R. Liu, F. Liu, K.-L. Wu, J. Li, X.-H. Liu, C.-L. Zhu, Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, *Clinical Chemistry and Laboratory Medicine* 58 (7) (2020) 1116–1120. doi: 10.1515/cc1m-2020-0188.
- [6] X. Bi, Z. Su, H. Yan, J. Du, J. Wang, L. Chen, M. Peng, S. Chen, B. Shen, J. Li, Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count, *Platelets* 31 (5) (2020) 674–679. doi: 10.1080/09537104.2020.1760230.
- [7] F. Liu, L. Li, M. Xu, J. Wu, D. Luo, Y. Zhu, B. Li, X. Song, X. Zhou, Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19, *Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology* 127 (2020) 104370. doi: 10.1016/j.jcv.2020.104370.
- [8] G. Vaseghi, M. Mansourian, R. Karimi, K. Heshmat-Ghahdarjani, P. Rouhi, M. Shariati, S. H. Javanmard, Inflammatory markers in Covid-19 Patients: A systematic review and meta-analysis, *medRxiv* (2020) 2020.04.29.20084863 doi: 10.1101/2020.04.29.20084863.
- [9] Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, *Intensive Care Medicine* 46 (5) (2020) 846–848. doi: 10.1007/s00134-020-05991-x.
- [10] B. E. Young, S. W. X. Ong, S. Kalimuddin, J. G. Low, S. Y. Tan, J. Loh, O.-T. Ng, K. Marimuthu, L. W. Ang, T. M. Mak, S. K. Lau, D. E. Anderson, K. S. Chan, T. Y. Tan, T. Y. Ng, L. Cui, Z. Said, L. Kurupatham, M. I.-C. Chen, M. Chan, S. Vasoo, L.-F. Wang, B. H. Tan, R. T. P. Lin, V. J. M. Lee, Y.-S. Leo, D. C. Lye, Singapore 2019 Novel Coronavirus Outbreak Research Team, Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore, *JAMA* 323 (15) (2020) 1488–1494. doi: 10.1001/jama.2020.3204.
- [11] J. Liu, Y. Liu, P. Xiang, L. Pu, H. Xiong, C. Li, M. Zhang, J. Tan, Y. Xu, R. Song, M. Song, L. Wang, W. Zhang, B. Han, L. Yang, X. Wang, G. Zhou, T. Zhang, B. Li, Y. Wang, Z. Chen, X. Wang, Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage, *medRxiv* (2020) 2020.02.10.20021584 doi: 10.1101/2020.02.10.20021584.
- [12] L. E. Gralinski, A. Bankhead, S. Jeng, V. D. Menachery, S. Proll, S. E. Belisle, M. Matzke, B.-J. M. Webb-Robertson, M. L. Luna, A. K. Shukla, M. T. Ferris, M. Bolles, J. Chang, L. Aicher, K. M. Waters, R. D. Smith, T. O. Metz, G. L. Law, M. G. Katze, S. McWeeney, R. S. Baric, Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury, *mBio* 4 (4) (Aug. 2013). doi: 10.1128/mBio.00271-13.
- [13] Z. Xu, L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao, H. Liu, L. Zhu, Y. Tai, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao, F.-S. Wang, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, *The Lancet Respiratory Medicine* 8 (4) (2020) 420–422. doi: 10.1016/S2213-2600(20)30076-X.
- [14] M. Arentz, E. Yim, L. Klaff, S. Lokhandwala, F. X. Riedo, M. Chong, M. Lee, Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State, *JAMA* 323 (16) (2020) 1612–1614. doi: 10.1001/jama.2020.4326.
- [15] N. Wilson, A. Kvalsvig, L. T. Barnard, M. G. Baker, Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality - Volume 26, Number 6—June 2020 - *Emerging Infectious Diseases journal - CDC, Emerging Infectious Diseases* (2020). doi: 10.3201/eid2606.200320.

- 647 [16] H. Barrasa, J. Rello, S. Tejada, A. Martín, G. Balziskueta, C. Vin-  
648 uesa, B. Fernández-Míret, A. Villagra, A. Vallejo, A. San Sebastián,  
649 S. Cabañes, S. Iribarren, F. Fonseca, J. Maynar, Alava COVID-19 Study  
650 Investigators, SARS-CoV-2 in Spanish Intensive Care Units: Early experi-  
651 ence with 15-day survival in Vitoria, Anaesthesia, Critical Care & Pain  
652 Medicine 39 (5) (2020) 553–561. doi:10.1016/j.accpm.2020.04.  
653 001.
- 654 [17] L. Wynants, B. V. Calster, G. S. Collins, R. D. Riley, G. Heinze, E. Schuit,  
655 M. M. J. Bonten, D. L. Dahly, J. A. Damen, T. P. A. Debray, V. M. T.  
656 de Jong, M. D. Vos, P. Dhiman, M. C. Haller, M. O. Harhay, L. Henck-  
657 aerts, P. Heus, M. Kammer, N. Kreuzberger, A. Lohmann, K. Luijken,  
658 J. Ma, G. P. Martin, D. J. McLernon, C. L. A. Navarro, J. B. Reitsma,  
659 J. C. Sergeant, C. Shi, N. Skoetz, L. J. M. Smits, K. I. E. Snell, M. Sper-  
660 rin, R. Spijker, E. W. Steyerberg, T. Takada, I. Tzoulaki, S. M. J. van  
661 Kuijk, B. C. T. van Bussel, I. C. C. van der Horst, F. S. van Royen, J. Y.  
662 Verbakel, C. Wallisch, J. Wilkinson, R. Wolff, L. Hooft, K. G. M. Moons,  
663 M. van Smeden, Prediction models for diagnosis and prognosis of covid-  
664 19: Systematic review and critical appraisal, *BMJ* 369 (2020) m1328.  
665 doi:10.1136/bmj.m1328.
- 666 [18] R. Tibshirani, Regression Shrinkage and Selection Via the Lasso, *Journal*  
667 *of the Royal Statistical Society: Series B (Methodological)* 58 (1) (1996)  
668 267–288. doi:10.1111/j.2517-6161.1996.tb02080.x.
- 669 [19] J. Piironen, M. Paasiniemi, A. Vehtari, Projective inference in high-  
670 dimensional problems: Prediction and feature selection, *Electronic Jour-  
671 nal of Statistics* 14 (1) (2020) 2155–2197. doi:10.1214/20-EJS1711.
- 672 [20] J. C. Marshall, S. Murthy, J. Diaz, N. Adhikari, D. C. Angus, Y. M. Arabi,  
673 K. Baillie, M. Bauer, S. Berry, B. Blackwood, et al., A minimal common  
674 outcome measure set for covid-19 clinical research, *The Lancet Infectious*  
675 *Diseases* 20 (8) (2020) e192–e197.
- 676 [21] M. van der Schaar Lab, Time series in healthcare: challenges and  
677 solutions, [https://www.vanderschaar-lab.com/time-series-in-healthcare/](https://www.vanderschaar-lab.com/time-series-in-healthcare/(2022))  
678 (2022).
- 679 [22] C. M. Carvalho, N. G. Polson, J. G. Scott, Handling sparsity via the horse-  
680 shoe, in: *Artificial Intelligence and Statistics*, PMLR, 2009, pp. 73–80.
- 681 [23] Variable selection – A review and recommendations for the practicing  
682 statistician - Heinze - 2018 - *Biometrical Journal* - Wiley Online Library,  
683 <https://onlinelibrary.wiley.com/doi/full/10.1002/bimj.201700067> (2018).
- 684 [24] R. H. Groenwold, Informative missingness in electronic health record sys-  
685 tems: the curse of knowing, *Diagnostic and prognostic research* 4 (1)  
686 (2020) 1–6.
- 687 [25] S. Van Buuren, *Flexible imputation of missing data*, CRC press, 2018.
- 688 [26] D. G. Altman, P. Royston, The cost of dichotomising continuous vari-  
689 ables, *BMJ : British Medical Journal* 332 (7549) (2006) 1080.
- 690 [27] S. R. Knight, A. Ho, R. Pius, I. Buchan, G. Carson, T. M. Drake, J. Dun-  
691 ning, C. J. Fairfield, C. Gamble, C. A. Green, et al., Risk stratification of  
692 patients admitted to hospital with covid-19 using the isaric who clinical  
693 characterisation protocol: development and validation of the 4c mortality  
694 score, *bmj* 370 (2020).
- 695 [28] J. Zhou, S. Lee, X. Wang, Y. Li, W. K. K. Wu, T. Liu, Z. Cao, D. D. Zeng,  
696 K. S. K. Leung, A. K. C. Wai, et al., Development of a multivariable  
697 prediction model for severe covid-19 disease: a population-based study  
698 from hong kong, *NPJ digital medicine* 4 (1) (2021) 1–9.
- 699 [29] E. Carr, R. Bendayan, D. Bean, M. Stammers, W. Wang, H. Zhang,  
700 T. Searle, Z. Kraljevic, A. Shek, H. T. T. Phan, W. Muruet, R. K. Gupta,  
701 A. J. Shinton, M. Wyatt, T. Shi, X. Zhang, A. Pickles, D. Stahl, R. Zak-  
702 eri, M. Noursadeghi, K. O'Gallagher, M. Rogers, A. Folarin, A. Karwath,  
703 K. E. Wickstrøm, A. Köhn-Luque, L. Slater, V. R. Cardoso, C. Bour-  
704 deaux, A. R. Holten, S. Ball, C. McWilliams, L. Roguski, F. Borca,  
705 J. Batchelor, E. K. Amundsen, X. Wu, G. V. Gkoutos, J. Sun, A. Pinto,  
706 B. Guthrie, C. Breen, A. Douiri, H. Wu, V. Curcin, J. T. Teo, A. M. Shah,  
707 R. J. B. Dobson, Evaluation and improvement of the National Early  
708 Warning Score (NEWS2) for COVID-19: A multi-hospital study, *BMC*  
709 *Medicine* 19 (1) (2021) 23. doi:10.1186/s12916-020-01893-3.

Missing values map




Figure S1: Heat map displaying missing values across recorded biomarkers. Light blue indicates a value is missing and dark blue indicate it is present

Patient Visualisation




Figure S2: Example biomarker time series for a patient admitted to hospital COVID-19 positive and who subsequently died almost two weeks later.

Patient Visualisation




Figure S3: Example biomarker time series for a patient admitted to hospital with subsequent nosocomial transmission and discharge a week later.




Figure S4: Example biomarker time series for a patient admitted to hospital COVID-19 positive, with subsequent entrance to ICU and death over one month later.




Figure S5: Example biomarker time series for a patient admitted to hospital and ICU, with subsequent nosocomial transmission and discharge about one week later.




Figure S7: Distribution of D-Dimer readings with clinical classification requiring age and gender bands




Figure S6: Example biomarker time series for a patient with two hospital admissions and testing COVID-19 positive on the first, with discharge almost two weeks after second admission.

Biomarker	Binary Categorical Variable	P-Value	Odds Ratio CI [2.5%, 97.5%]
<b>Demographics / Other</b>			
Age	-	6.30E-05	1.04 [1.02, 1.06]
Gender	Female	0.43	1.21 [0.75, 1.97]
<b>Blood Clotting Tests</b>			
Activated partial thromboplastin time	Mild	0.07	2.79 [0.93, 8.35]
	Moderate	0.99	3.23E+07 [0, Inf]
	Not Taken	0.50	0.45 [0.05, 4.51]
Prothrombin Time	Abnormal	0.16	2.02 [0.75, 5.44]
	Not Taken	0.46	2.38 [0.24, 23.86]
<b>Blood Gas Tests</b>			
Carbon Dioxide	Abnormal	0.80	1.13 [0.44, 2.95]
	Not Taken	NA	NA
Lactate	Abnormal	0.63	0.67 [0.13, 3.34]
	Not Taken	0.02	0.16 [0.04, 0.72]
Oxygen	Abnormal	0.95	1.05 [0.26, 4.15]
	Not Taken	NA	NA
Bicarbonate Excess	Abnormal	0.24	1.48 [0.76, 2.87]
	Not Taken	0.99	0 [0, Inf]
pH acid/base scale	Abnormal	0.13	1.59 [0.87, 2.91]
	Not Taken	0.99	9.4E06 [0, Inf]
<b>Coinfection</b>			
Blood Culture	TRUE	0.99	0 [0, Inf]
Respiratory	TRUE	0.36	2.71 [0.32, 22.69]
Urine	TRUE	0.43	0.45 [0.06, 3.24]
Viral	TRUE	0.02	16.64 [1.7, 162.66]
<b>Diabetes</b>			
Glucose	Abnormal	0.36	1.55 [0.61, 3.92]
	Not Taken	0.60	0.84 [0.44, 1.61]
<b>Full Blood Count Tests</b>			
Hemoglobin	Mild	0.05	1.76 [1.01, 3.09]
	Moderate	0.99	1.01 [0.40, 2.51]
	Severe	0.15	4.62 [0.58, 37.05]
	Not Taken	0.99	1.3E9 [0, Inf]
Platelet Count	Mild	0.01	2.8 [1.33, 5.90]
	Moderate	0.03	5.81 [1.21, 28.03]
	Severe	0.10	20.44 [0.57, 734.84]
	Not Taken	0.99	0 [0, Inf]
Lymphocytes	Mild	0.12	1.98 [0.83, 4.73]
	Moderate	0.23	1.81 [0.69, 4.76]
	Severe	0.14	2.61 [0.74, 9.22]
	Not Taken	NA	NA
Neutrophils	Mild	0.02	0.05 [4E-3, 0.59]
	Moderate	0.73	0.22 [3.1E-5, 1.4E3]
	Severe	0.38	1.45 [0.63, 3.32]
	Not Taken	NA	NA
Neutrophil - Lymphocyte Ratio	Mild	0.82	1.1 [0.48, 2.52]
	Moderate	0.80	1.15 [0.39, 3.44]
	Severe	0.41	1.89 [0.41, 8.69]
	Not Taken	NA	NA
White Cell Count	Mild	0.72	0.83 [0.29, 2.38]
	Moderate	0.73	0.21 [2.5E-5, 1.6E3]
	Severe	0.83	1.11 [0.43, 2.83]
	Not Taken	NA	NA
<b>Urea &amp; Electrolytes Tests</b>			
C-Reactive Protein	Abnormal	0.07	4.46 [0.91, 21.93]
	Not Taken	0.94	0.90 [0.07, 12.34]
Estimated Glomerular Filtration Rate	Abnormal	0.41	0.72 [0.33, 1.58]
	Not Taken	0.04	0.25 [0.06, 0.95]
Urea	Abnormal	3.71E-04	2.74 [1.57, 4.77]
	Not Taken	0.95	0.94 [0.11, 7.76]
<b>Investigatory Tests</b>			
Brain / B-type natriuretic peptide	Abnormal	0.72	1.47 [0.18, 11.76]
	Not Taken	0.81	1.24 [0.21, 7.40]
D-Dimer	Abnormal	0.31	0.42 [0.08, 2.24]
	Not Taken	0.23	0.37 [0.07, 1.89]
Ferritin	Mild	0.10	5.65 [0.71, 45.00]
	Moderate	0.61	1.52 [0.30, 7.58]
	Severe	0.84	1.30 [0.10, 17.54]
	Not Taken	0.63	1.30 [0.45, 3.72]
Fibrinogen	Mild	0.21	11.93 [0.26, 552.59]
	Severe	0.42	0.26 [0.01, 6.77]
	Not Taken	0.92	1.07 [0.27, 4.22]
Lactate dehydrogenase	Mild	0.13	14.88 [0.46, 477.41]
	Moderate	0.31	5.41 [0.20, 145.69]
	Severe	0.48	4.20 [0.08, 217.62]
	Not Taken	0.61	2.13 [0.12, 39.40]
Troponin-T	Abnormal	0.68	1.31 [0.37, 4.65]
	Not Taken	0.58	1.40 [0.43, 4.53]
<b>Intercept</b>			
Intercept	-	0.004	0.001 [0.0, 0.11]




Figure S9: Model calibration depicting a standard GLM model trained on: (Top) all data and tested on all data (Middle); training data (n=590) and tested on the same; (Bottom) training data and tested on validation data (n=293). A well calibrated model should evenly distribute outcome probabilities, i.e. be close to unity.

Figure S8: Standard logistic regression odds ratio and confidence intervals per biomarker using all valid biomarker training data available (n=590). Note most biomarkers include a 'Test Not Taken' stand in variable.




Figure S10: Frequency of LASSO logistic regression variables having a coefficient greater or less than 0. Red and black lines indicate thresholds for 20% and 50% frequency.





Solution Terms	AUC	Difference	ELPD LOO	Standard Error	Difference	Standard Error
<NA>	0	-0.8	-358.5	9.7	-61.6	10.7
UreaAbnormal	0.5	-0.3	-326.3	11.4	-29.4	8.3
poctLACNA	0.6	-0.2	-310.6	12.2	-13.6	6.4
O2NA	0.6	-0.2	-310.6	12.2	-13.6	6.4
CO2NA	0.6	-0.2	-310.5	12.1	-13.6	6.3
Age	0.8	0	-302.2	11.9	-5.3	5
PTAbnormal	0.8	0	-299.2	12	-2.2	4.3
NLRSevere	0.8	0	-307.6	12.3	-10.7	4
LDHNA	0.8	0	-304.7	12.5	-7.8	3.7
poctpHAbnormal	0.8	0	-302.3	12.4	-5.4	3.4
LymphocytesSevere	0.8	0	-302.9	12.4	-5.9	3.4
APTTMild	0.8	0	-301.4	12.4	-4.5	3.4
eGFRAbnormal	0.8	0	-299	12.4	-2	3.3
NeutrophilsSevere	0.8	0	-301.8	12.6	-4.8	3.1
APTTModerate	0.8	0	-302.5	12.8	-5.6	3
FERNA	0.8	0	-304.7	12.8	-7.8	2.9
fibNA	0.8	0	-302.4	12.8	-5.4	2.8
CRPAbnormal	0.8	0	-303.1	12.7	-6.2	2.8
CO2Abnormal	0.8	0	-301.2	12.8	-4.3	2.7
DDMAbnormal	0.8	0	-302.4	12.7	-5.5	2.6
HBSevere	0.8	0	-302.9	12.8	-6	2.6

Figure S12: Summary statistics of Bayesian projective prediction ranking the contribution of each variable by change in AUC and expected log-predictive density (ELPD)

Biomarker	Binary Categorical Variable	Bayesian Horshoe Odds Ratios CI [2.5%, 97.5%]	Projective Prediction 3-Biomarker Model Odds Ratios CI [2.5%, 97.5%]
<b>Demographics / Other</b>			
Age	-	1.03 [1.02, 1.05]	1.02 [1, 1.03]
Gender	Female	0.99 [0.74, 1.3]	
<b>Blood Clotting Tests</b>			
Activated partial thromboplastin time	Mild	1.57 [0.87, 4.63]	
	Moderate	3.24 [0.81, 112.13]	
	Not Taken	0.93 [0.55, 1.32]	
Prothrombin Time	Abnormal	1.66 [0.91, 4.18]	2.32 [1.15, 4.61]
	Not Taken	0.99 [0.64, 1.55]	0.63 [0.41, 0.9]
<b>Blood Gas Tests</b>			
Carbon Dioxide	Abnormal	1.05 [0.69, 1.81]	
	Not Taken	0.64 [0.13, 1.6]	
Lactate	Abnormal	0.89 [0.36, 1.53]	
	Not Taken	0.63 [0.13, 1.58]	
Oxygen	Abnormal	1.1 [0.66, 2.52]	
	Not Taken	0.63 [0.13, 1.56]	
Bicarbonate Excess	Abnormal	1.13 [0.84, 1.91]	
	Not Taken	1.1 [0.68, 2.17]	
pH acid/base scale	Abnormal	1.3 [0.91, 2.31]	
	Not Taken	1.17 [0.78, 2.54]	
<b>Coinfection</b>			
Blood Culture	TRUE	0.6 [0.04, 1.4]	
Respiratory	TRUE	1.1 [0.56, 3.19]	
Urine	TRUE	0.94 [0.39, 1.72]	
Viral	TRUE	1.81 [0.77, 14.79]	
<b>Diabetes</b>			
Glucose	Abnormal	1.1 [0.76, 2.01]	
	Not Taken	0.96 [0.66, 1.3]	
<b>Full Blood Count Tests</b>			
Hemoglobin	Mild	1.11 [0.85, 1.7]	
	Moderate	1 [0.63, 1.54]	
	Severe	1.57 [0.77, 8.07]	
	Not Taken	1.3 [0.55, 8.27]	
Platelet Count	Mild	1.35 [0.89, 2.83]	
	Moderate	1.58 [0.83, 6.12]	
	Severe	1.41 [0.64, 11.32]	
	Not Taken	0.97 [0.34, 2.29]	
Lymphocytes	Mild	1.05 [0.76, 1.6]	
	Moderate	1.02 [0.75, 1.48]	
	Severe	1.2 [0.84, 2.35]	
	Not Taken	1.31 [0.56, 8.86]	
Neutrophils	Mild	0.66 [0.13, 1.27]	
	Moderate	1 [0.33, 2.96]	
	Severe	1.14 [0.82, 1.95]	
	Not Taken	1.31 [0.57, 8.9]	
Neutrophil - Lymphocyte Ratio	Mild	1.04 [0.77, 1.55]	1.32 [0.92, 2.29]
	Moderate	1.08 [0.79, 1.78]	1.98 [1.34, 3.38]
	Severe	1.38 [0.86, 3.41]	2.55 [1.5, 5.34]
	Not Taken	1.31 [0.57, 8.84]	3.22 [0.94, 14.32]
White Cell Count	Mild	0.91 [0.48, 1.35]	
	Moderate	1.04 [0.37, 3.61]	
	Severe	1.12 [0.78, 2]	
	Not Taken	1.29 [0.55, 8.15]	
<b>Urea &amp; Electrolytes Tests</b>			
C-Reactive Protein	Abnormal	2.04 [0.93, 7.61]	
	Not Taken	1.11 [0.55, 3.54]	
Estimated Glomerular Filtration Rate	Abnormal	1.03 [0.71, 1.6]	
	Not Taken	0.72 [0.26, 1.16]	
Urea	Abnormal	2.83 [1.72, 4.65]	3.28 [2.2, 5.2]
	Not Taken	1.07 [0.56, 2.53]	0.84 [0.25, 1.81]
<b>Investigatory Tests</b>			
Brain / B-type natriuretic peptide	Abnormal	1.05 [0.64, 1.99]	
	Not Taken	0.95 [0.53, 1.49]	
D-Dimer	Abnormal	1.07 [0.66, 2.08]	
	Not Taken	0.85 [0.4, 1.3]	
Ferritin	Mild	1.43 [0.75, 6.87]	
	Moderate	1.07 [0.65, 2.14]	
	Severe	1.01 [0.44, 2.35]	
	Not Taken	0.93 [0.56, 1.34]	
Fibrinogen	Mild	1.32 [0.61, 8.49]	
	Severe	0.92 [0.26, 2.21]	
	Not Taken	0.87 [0.39, 1.37]	
Lactate dehydrogenase	Mild	1.29 [0.7, 5.43]	
	Moderate	1.07 [0.56, 2.51]	
	Severe	1.05 [0.47, 2.96]	
	Not Taken	0.71 [0.24, 1.22]	
Troponin-T	Abnormal	1.01 [0.68, 1.55]	
	Not Taken	1.02 [0.71, 1.57]	
<b>Intercept</b>			
Intercept	-	0.04 [0.0, 0.28]	0.05 [0.02, 0.11]

Figure S13: Odds ratios for full Bayesian model and reduced 3-biomarker model via projective prediction




Figure S14: Model calibration depicting Projective Prediction 3-biomarker model tested on: (Top) training data (n=590); (Bottom) validation data (n=293). Note the models do not have points for each of the 10 probability bins because some ranges, e.g. 0.9-1.0 had no patients in this band as judged by the model output. A well calibrated model should evenly distribute outcome probabilities, i.e. be close to unity.